HIV Infections Clinical Trial
Official title:
International Trial of Modified Directly Observed Therapy Versus Self-Administered Therapy for Participants With First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen
Verified date | September 2018 |
Source | AIDS Clinical Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Highly active antiretroviral therapy (HAART) has led to better health and survival rates among people with HIV/AIDS. The purpose of this study was to measure the effect of trained partner supervision when taking medication versus self-administered therapy in HIV infected participants. These participants have had their first virologic failure on a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen and were starting a protease inhibitor (PI)-based HAART regimen at study entry.
Status | Completed |
Enrollment | 529 |
Est. completion date | September 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria for Participants: - HIV infected - Have experienced or currently experiencing first baseline virologic failure on first NNRTI-based HAART regimen with no history of virologic failure on another regimen OR discontinued first NNRTI-based HAART regimen without the recommendations of clinicians and currently experiencing virologic failure with no history of virologic failure on another regimen. More information on this criterion can be found in the protocol. - Confirmed virologic failure within 45 days of study entry - Receiving one of the following NNRTI-based regimens for at least 16 weeks prior to study entry: ZDV+3TC+NVP, ZDV+3TC+EFV, d4T+3TC+NVP or d4T+3TC+EFV - Able to identify a close friend, relative, or spouse who is willing to serve as a partner - Intend to stay in current geographical area of residence for the duration of the study - Agree to use LPV/rtv with MEMS caps and take the tablets out of the container only at dosing - Willing to use acceptable forms of contraception - Ability and willingness of participant or legal guardian/representative to give written informed consent. - Required laboratory values obtained within 45 days prior to study entry. - Negative serum or urine pregnancy test obtained within 48 hours prior to study entry for women of reproductive potential. Inclusion Criteria for Partners: - Not a participant - Friend, family member, or spouse who knows of the participant's HIV status. Partners do not have to live with participants. - Willing to attend a 1- to 2-hour taped training session prior to study entry - Willing to attend study visits with participant at study screening; entry; and Weeks 4, 8, 12, 24, and 52 - Willing to directly observe participant taking at least one dose of LPV/rtv for at least 5 days per week for 24 weeks after stratification of participant - Willing to act as a positive support for participant - Willing to notify clinical staff of participant's nonadherence to study assigned regimen - Willing to notify clinical staff if they are unable to provide mDOT for 2 weeks or more - Willing to complete medication diary logs - Willing to complete exit interview - Agree to have their training session taped (if required). - For mDOT arm, willing to discuss and decide with participants whether to continue mDOT after Week 24 - At least 18 years old - Understand that participants have agreed to use LPV/RTV with MEMS caps and take the tablets out of the container only at dosing - Ability and willingness to give written informed consent. - No intention to relocate away from current geographical area of residence for the duration of study participation. Exclusion Criteria for Participants: - Use of any immunomodulator, HIV vaccine, or other investigational therapy within 45 days of study entry - Prior treatment with any PI - Previously diagnosed cancer other than basal cell carcinoma and cutaneous Kaposi's sarcoma - Use of rifampin or rifabutin within 45 days of study entry or plan use of rifampin or rifabutin - Requirement for taking any medications that are prohibited by this study. More information on this criterion can be found in the protocol. - Known allergy to the study medications or their formulations - Current drug or alcohol use that, in the opinion of the investigator, would interfere with the study - Acute illness requiring hospitalization within 14 days of study entry - Active tuberculosis (TB) infection - Currently incarcerated - Participation as a partner in this study - Participation with no access to telephones - Abnormal laboratory values - Pregnant, breastfeeding, or intend to become pregnant Exclusion Criteria for Partners: - A participant in this study - Participation as a partner to any other participant - No access to telephones - Currently incarcerated |
Country | Name | City | State |
---|---|---|---|
Botswana | Gaborone Prevention/Treatment Trials CRS | Gaborone | |
Brazil | Instituto de Pesquisa Clinica Evandro Chagas (12101) | Rio de Janeiro | |
Haiti | Les Centres GHESKIO CRS | Bicentenaire | Port-au-Prince |
Peru | Barranco CRS | Lima | |
Peru | San Miguel CRS | San Miguel | Lima |
South Africa | Wits HIV CRS | Johannesburg | Gauteng |
Uganda | JCRC CRS | Kampala | |
Zambia | Kalingalinga Clinic CRS | Lusaka | |
Zimbabwe | UZ-Parirenyatwa CRS | Harare |
Lead Sponsor | Collaborator |
---|---|
AIDS Clinical Trials Group | National Institute of Allergy and Infectious Diseases (NIAID) |
Botswana, Brazil, Haiti, Peru, South Africa, Uganda, Zambia, Zimbabwe,
Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May;4(2):65-72. Review. — View Citation
Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S14-8. Review. — View Citation
Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep. 2007 Jul-Aug;122(4):472-81. — View Citation
Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, Gloyd SS. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):238-44. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Confirmed Virologic Failure at or Prior to Week 48 | Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) <1 log10 copies/mL below the baseline level and >400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) >400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so =50 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 48 was reported. | At or prior to Week 48 | |
Secondary | Confirmed Virologic Failure at or Prior to Week 24 | Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) <1 log10 copies/mL below the baseline level and >400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) >400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so =30 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 24 was reported. | At or prior to Week 24 | |
Secondary | CD4 Count at Follow-up Visits | CD4 cell count (median, inter-quartile range) | At Weeks 4, 12, 24, 36, and 48 | |
Secondary | CD8 Count at Follow-up Visits | CD8 cell count (median, inter-quartile range) | At week 4, 12, 24, 36, and 48 | |
Secondary | Time to First Grade 3 or 4 Lab Event | 5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab event | 52 weeks since randomization | |
Secondary | Time to First Grade 3 or 4 Sign or Symptom | 5th and 10th percentiles in weeks from randomization to first grade 3 or 4 sign or symptom | 52 weeks since randomization | |
Secondary | Time to First Grade 3 or 4 Lab or Sign/Symptom Event | 5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab or sign/ symptom event | 52 weeks since randomization | |
Secondary | Adherence to Second Line HAART Regimen | Number of participants with self-reported 100% adherence over the week prior to study visit | At weeks 4, 8, 12, 24, 36, 48 and 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |